Pargluva Effect: Bristol Foresees More Independent Scrutiny Of Trial Data
Executive Summary
Greater availability of clinical trial data through online databases could lead to more independent reviews of study results akin to a published analysis of Pargluva data, Bristol-Myers Squibb U.S. Pharmaceuticals President Anthony Hooper speculated during a press meeting Nov. 18
You may also be interested in...
Rx Industry May Need To Inject More Funds Into R&D – GSK Exec
Pharmaceutical manufacturers should consider increasing research & development investments to sustain growth, GlaxoSmithKline R&D Chairman Tachi Yamada declared during a Nov. 30 pipeline update
Rx Industry May Need To Inject More Funds Into R&D – GSK Exec
Pharmaceutical manufacturers should consider increasing research & development investments to sustain growth, GlaxoSmithKline R&D Chairman Tachi Yamada declared during a Nov. 30 pipeline update
Pargluva Panic: Need For Additional Trial Prompts Merck To Drop Partnership
Bristol-Myers Squibb remains in discussions with FDA about what clinical studies would be required to address concerns about the cardiovascular safety profile of its type 2 diabetes treatment candidate Pargluva (muraglitazar)